| Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss A Fedoriw, SR Rajapurkar, S O'Brien, SV Gerhart, LH Mitchell, ND Adams, ... Cancer cell 36 (1), 100-114. e25, 2019 | 238 | 2019 |
| Genetic variation determines PPARγ function and anti-diabetic drug response in vivo RE Soccio, ER Chen, SR Rajapurkar, P Safabakhsh, JM Marinis, ... Cell 162 (1), 33-44, 2015 | 128 | 2015 |
| Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across … KN Smitheman, TM Severson, SR Rajapurkar, MT McCabe, N Karpinich, ... haematologica 104 (6), 1156, 2019 | 62 | 2019 |
| Targeting PPARγ in the epigenome rescues genetic metabolic defects in mice RE Soccio, Z Li, ER Chen, YH Foong, KK Benson, JR Dispirito, ... The Journal of clinical investigation 127 (4), 1451-1462, 2017 | 50 | 2017 |
| MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers A Wyce, JJ Matteo, SW Foley, DJ Felitsky, SR Rajapurkar, XP Zhang, ... Oncogenesis 7 (4), 35, 2018 | 32 | 2018 |
| Inhibiting type I arginine methyltransferase activity promotes T cell–mediated antitumor immune responses A Fedoriw, L Shi, S O'Brien, KN Smitheman, Y Wang, J Hou, C Sherk, ... Cancer immunology research 10 (4), 420-436, 2022 | 17 | 2022 |
| 624 Targeting Type I arginine methyltransferases promotes T cell mediated antitumor immune responses L Shi, A Fedoriw, S O’Brien, K Smitheman, Y Wang, J Hou, C Sherk, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A654-A654, 2021 | | 2021 |
| Citarinostat inhibitor S GSK3368715, A Fedoriw, SR Rajapurkar, G O’Brien, SV Gerhart, ... | | |
